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408 The Journal of Thoracic and CardioBackground: Cisplatin-based chemotherapy followed by surgical extirpation of
residual benign disease represents the usual sequence of curative therapy for
metastatic nonseminomatous germ cell cancer of testicular origin. Occasionally,
residual disease is malignant in the form of either a persistent nonseminomatous
germ cell cancer tumor or degeneration into non–germ cell cancer. We reviewed our
institution’s experience with patients undergoing salvage operations to remove
malignant intrathoracic metastases.
Methods: From 1981 through 2001, 438 patients with nonseminomatous germ cell
cancer had operations to remove residual intrathoracic disease after cisplatin-based
chemotherapy at Indiana University Hospital. A subset of 134 patients who under-
went 186 surgical procedures to remove malignant metastases is the basis of this
review. Fifty-nine patients had removal of pulmonary metastases, 49 had removal of
mediastinal metastases, and 26 had removal of both pulmonary and mediastinal
metastases. Surgical pathology demonstrated 84 patients with persistent nonsemi-
nomatous germ cell cancer tumors, 38 with degeneration into non–germ cell cancer,
and 12 with both malignant pathologic categories.
Results: There were 4 (3.7%) operative deaths. The overall median survival was 5.6
years, with 55 (42.3%) patients alive and well after a mean follow-up of 5.1 years.
Seventeen variables were analyzed by using Cox regression. Of these, older age,
pulmonary metastases (vs mediastinal metastases), and 4 or more (vs 1) total intratho-
racic metastases were significantly (P  .01) predictive of inferior long-term survival.
Conclusions: Salvage thoracic surgery to remove malignant metastases from nonsemi-
nomatous germ cell cancer tumors of testicular origin can result in long-term survival in
select patients. We identified variables that influence survival in this subset.
Nonseminomatous germ cell tumors (NSGCTs) of testicular origin are themost common neoplasm in young male subjects less than 35 years of age.1Approximately 8000 new cases will be diagnosed in the United States each
year, with the worldwide incidence doubling during the past 40 years.2 Despite the
increasing incidence of testicular NSGCTs, mortality rates have dramatically de-
creased since the advent of cisplatin-based chemotherapy. Cisplatin-based chemo-
therapy alone results in 70% to 80% durable cure for patients presenting with
disseminated disease. It is estimated that 10% to 20% of patients with testicular
NSGCTs who present with or subsequently have supradiaphragmatic metastases
will require at least one thoracic surgical procedure in the form of either mediastinal
dissection, pulmonary metastasectomy, or both, to remove residual disease after
chemotherapy.3 The vast majority of these cases will involve removal of benign
disease in the form of mature teratoma, tumor necrosis, or both, with an excellent
long-term prognosis anticipated.4-6 The subset of patients who undergo removal of
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patients with persistent NSGCTs after first- or second-line
chemotherapy, late NSGCT relapse, and NSGCT degener-
ation into non–germ cell cancer (NGCCA).6,7 We under-
took an institutional review of patients who underwent
thoracic surgery to remove malignant metastases from NS-
GCTs of testicular origin to determine variables predictive
of outcome.
Materials and Methods
Patient Variables
Institutional records of 483 patients with the diagnosis of testicular
NSGCT who underwent removal of residual intrathoracic disease
after cisplatin-based chemotherapy between 1981 and 2001 were
reviewed after institutional review board approval. We identified a
subset of 134 patients who had undergone at least one thoracic
surgical procedure to remove malignant metastases. The following
variables were recorded when available: age, serum tumor markers
(STMs; -fetoprotein and the  subunit of human chorionic go-
nadotropin [bHCG]) at diagnosis and at the time of surgical
intervention, stage at presentation (I, testes; II, retroperitoneum;
III, supradiaphragmatic; III advanced, liver or brain metastases),
testicular pathology (NSGCT cell type or types, the presence of
teratoma or NGCCA), second-line chemotherapy (cisplatin-based
or high-dose cisplatin-based therapy plus autologous stem cell
transplantation) before surgical intervention, concomitant or sep-
arate retroperitoneal lymph node dissection (RPLND), worst pa-
thology of RPLND (necrosis, teratoma, persistent NSGCT, or
NGCCA), presence and location of extrathoracic malignant me-
tastases, time from diagnosis to the first thoracic surgical proce-
dure to remove malignant disease, number of thoracic surgical
procedures to remove malignant metastases, location and number
of intrathoracic malignant metastases (lung, mediastinum, or both),
type of pulmonary resection (wedge, lobectomy, and/or pneumo-
nectomy), location and type of mediastinal dissection (upper-
middle-lower visceral, anterior, and/or paravertebral sulcus com-
partments6-8), adjacent organs removed, pathology of malignant
metastases (persistent NSGCT [persistent nonseminomatous germ
cell cancer], NGCCA [degeneration into sarcoma, primitive neu-
roectodermal tumor, adenocarcinoma, and/or undifferentiated car-
cinoma], or both persistent NSGCT and NGCCA), operative mor-
bidity and mortality, and status at last follow-up.
Indications and Techniques of Surgical Intervention
Our indications and techniques for thoracic surgery to remove
residual disease after chemotherapy for both routine and salvage
cases have previously been described.6,7 In summary, salvage
thoracic surgery was typically performed for patients suspected of
having malignant pathology, which included persistent NSGCTs
after first- or second-line chemotherapy, late NSGCT relapse (2
years after initial chemotherapy), and/or degeneration into
NGCCA. The 2 former indications are usually identified on the
basis of the increase of STM levels, and thus biopsy of intratho-
racic masses on computed tomographic (CT) scanning in this
clinical setting is rarely necessary. The latter indication to remove
NGCCA can be more difficult to determine preoperatively because
STM levels are frequently normal. However, NGCCA pathology
The Journal of Thoracican also be anticipated without biopsy on the basis of similar
pathology from prior nonthoracic surgery, such as RPLND; a
noncystic appearance on CT imaging; or both.7 We have advo-
cated surgical therapy for all patients suspected of having terato-
matous pathology after chemotherapy regardless of the extent of
intrathoracic disease because not only are conservative surgical
techniques that spare pulmonary parenchyma, intrathoracic nerves,
and blood vessels appropriate, but also the prognosis is excellent
after successful surgical intervention.6 In contrast, we have main-
tained a more conservative approach to patient selection when
malignant disease is suspected, reserving salvage thoracic surgery
for patients with a limited number of intrathoracic or extrathoracic
metastases. Although positron emission tomograpic (PET) scan-
ning has low diagnostic yield for the majority of patients with
benign residual disease, such as teratoma or necrosis, PET imaging
can identify areas of malignant disease and is of value for both
diagnostic and therapeutic decision-making purposes in these
cases.9 The ultimate decision to offer surgical intervention in this
series was made on an individual patient basis and collectively by
medical oncologists and thoracic surgeons. In general, surgical
intervention was offered if more than one area of intrathoracic
malignant disease could be removed at a relatively low operative
risk level or only one area of malignant disease was identifiable
that required a major surgical procedure, such as pneumonectomy
or en bloc removal of a great vessel. CT evidence, PET evidence,
or both, of multiple sites of malignant disease would typically
contraindicate surgical intervention.
In contrast to benign residual disease, not only are the indica-
tions for thoracic surgery more conservative for patients with
NSGCTs with malignant disease, but a more aggressive surgical
oncologic approach is occasionally necessary. Residual teratoma-
tous disease in the lung can frequently be excised with precision
electrocautery techniques, which spares parenchyma.10 In this
series, for patients in whom malignant disease was suspected,
however, standard wedge resection techniques were used that
included a surgical margin of normal lung tissue. Because of the
location or extent of pulmonary disease, anatomic resection in the
form of lobectomy or pneumonectomy was occasionally required.
For mediastinal disease, a more aggressive surgical approach com-
pared with the more common situation in which teratoma is
present was also occasionally necessary, removing portions of
adherent adjacent organs, great vessels, or both. Intraoperative
frozen section analysis was also used to assess surgical margins
after removal of suspected malignant disease if resection of addi-
tional adjacent tissue could be performed without adding signifi-
cant morbidity.
Our routine for postoperative care has been described in detail
elsewhere.7 In summary, because most patients received bleomy-
cin as part of first-line cisplatin-based chemotherapy regimens,
both perioperative fluid administration and inspired oxygen con-
centrations were minimized. If persistent NSGCT elements were
present after first-line chemotherapy, then administration of 2
additional cycles of cisplatin combination chemotherapy was
given postoperatively after satisfactory recovery.11,12 Patients who
pathologically demonstrated NGCCA or patients who received
second-line cisplatin-based chemotherapy before surgical inter-
vention were not given adjuvant cisplatin-based chemotherapy.
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Kaplan-Meier analysis was used to calculate survival from the
time of the first intrathoracic surgical procedure to remove malig-
TABLE 1. Demographics at surgical intervention
AFP, ng/mL (n  126)
Normal 81 (64.3)
25-100 19 (15.1)
101-1000 15 (11.9)
1001-10,000 11 (8.7)
bHCG, ng/mL (n  123)
Normal 92 (74.8)
1.5-1000 29 (23.6)
1001-50,000 2 (1.6)
Previous thoracic surgery procedures for benign disease
None 105 (78.4)
1 24 (17.9)
2 5 (3.7)
No. of thoracic surgery procedures to remove malignant disease
1 90 (67.2)
2 37 (27.6)
3 6 (4.5)
4 1 (0.7)
No. of lung metastases removed
None 49 (36.6)
1 43 (32.0)
2 15 (11.2)
3 10 (7.5)
4 17 (12.7)
Type of pulmonary resection*
Wedge 65 (76.5)
Segment-lobe 24 (28.2)
Pneumonectomy† 14 (16.5)
No. of mediastinal metastases removed
None 59 (44.0)
1 64 (47.8)
2 7 (5.2)
3 4 (2.9)
Type of mediastinal dissection*
Visceral
Upper 33 (44.0)
Middle 39 (52.0)
Lower 27 (36.0)
Anterior 4 (5.3)
Paravertebral sulcus 8 (10.6)
Adjacent organs 15 (20.0)
Descending aorta 3
Brachiocephalic artery 3
Chest wall–diaphragm 5
Esophageal wall 2
SVC–great vein 2
The number of patients is given, with the percentage of known variables in
parentheses. AFP, -Fetoprotein; bHCG,  subunit of human chorionic
gonadotropin; SVC, Superior vena cava. *Percentage of subset undergo-
ing either pulmonary or mediastinal surgery. †Pneumonectomy or equiva-
lent with 2 lobectomies.nant disease. Seventeen variables potentially predictive of long-
410 The Journal of Thoracic and Cardiovascular Surgery ● Auguterm survival were evaluated. Univariate assessments of discrete
risk factors possibly predictive of survival were made by using the
Kaplan-Meier method with log-rank tests. The Cox proportional
hazard model was used to calculate hazard ratios for both contin-
uous and discrete variables.
Results
Demographics at Diagnosis
The mean age at diagnosis was 27.8 years (range, 14-57 years).
From available data, 45 (19.2%) patients had either stage I or
II disease, and 87 (65.9%) patients demonstrated stage III
disease. Of the patients with stage III disease, 46 patients had
mediastinal disease, and 60 patients had lung metastases. The
most common testicular pathology was embryonal carcinoma,
which was present in 88 (68.2%) patients. Teratoma was
present in 78 (60.5%) patients, whereas 13 (10.1%) patients
demonstrated NGCCA in testis pathology. Eighty-one (60.4%)
patients received second-line cisplatin-based chemotherapy
(high-dose chemotherapy with autologous stem cell transplan-
tation, n 17) for progressive disease either during or shortly
after first-line cisplatin-based chemotherapy.13 One hundred
ten (82.1%) patients underwent RPLND before thoracic sur-
gery, with 60 demonstrating either persistent NSGCT or
NGCCA in the surgical specimen. Thirty-four patients under-
went RPLND in conjunction with the thoracic surgical proce-
dure. Twenty-two of these patients demonstrated malignant
pathology in both the RPLND and thoracic surgical specimens.
Thirteen patients underwent surgical intervention to remove
malignant metastases outside of the chest and abdomen (7 in
the neck, 2 in the brain, and 4 at other sites).
Surgical Intervention and Pathology
The average time from diagnosis to the first thoracic surgi-
cal procedure to remove malignant disease was 4.1 years
(range, 0.7-24.5 years). However, slightly more than half of
the series, 68 (50.7%) patients, underwent thoracic surgery
for malignant disease within 2 years of diagnosis, with the
remaining 66 (49.3%) patients undergoing thoracic salvage
surgery 2 or more years after initial diagnosis. Of the 130
patients who had known STM status at the time of the first
thoracic surgery to remove malignant disease, 72 (55.4%)
presented to surgical intervention with increased STM lev-
els, and 58 (44.6%) had normal STM levels (Table 1). There
were a total of 186 thoracic surgical procedures to remove
malignant disease. Fifty-nine (44.0%) patients had malig-
nant disease removed from the lung, 49 (36.6%) underwent
mediastinal dissection, and 26 (19.4%) had malignant dis-
ease removed from both the lung and the mediastinum.
Fifty-six (41.8%) patients had one metastasis removed from
the lung or mediastinum, 34 (25.4%) had 2 areas of malig-
nant disease removed, 16 (11.9%) had 3 areas of malignant
disease removed, and the remaining 28 (20.9%) had 4 or
more areas of malignant intrathoracic disease removed.
Eighty-four (62.7%) patients pathologically demonstrated
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12 (8.9%) demonstrated both types of malignant pathology.
Finally, 35 patients who pathologically demonstrated per-
sistent NSGCTs after first-line chemotherapy received 2
additional cycles of cisplatin-based chemotherapy after sur-
gical intervention.
Outcomes
The overall surgical mortality was 4 patients (3.6% of
patients and 2.2% of surgical procedures), all of whom
died as a result of respiratory (acute respiratory distress
syndrome–pneumonia) complications. Two of these 4
patients underwent pneumonectomy. One operative death
followed a lobectomy, and the remaining death occurred
after multiple pulmonary wedge resections. Twenty pa-
tients (14.9% of patients and 10.7% of procedures) had
significant nonfatal complications, including 8 patients
successfully treated for acute respiratory distress syn-
drome-pneumonia, 7 patients with prolonged air leak
(10 days), and 3 patients with prolonged chyle leak
(10 days). One patient had transient lower extremity
weakness after extensive lower visceral mediastinal dis-
section, and 1 patient required temporary dialysis. The
overall median survival was 5.8 years, with 55 (42.3%)
TABLE 2. Cox regression analysis of survival
Variable
At diagnosis
Age
AFP
bHCG
Stage
Lung disease
Mediastinal disease
Testes pathology
Teratoma
NGCCA
At surgical intervention
From diagnosis to cancer surgery (y)
AFP
bHCG
Extrathoracic cancer removed
No. of thoracic operations for cancer
Location of cancer
No. of lung metastases
No. of mediastinal metastases
No. of lung and mediastinal metastases
Pathology
Variables at surgical intervention: bHCG, normal versus increased; preope
mediastinum only versus lung only versus both mediastinum and lung; lun
more; no. of lung and mediastinal metastases, 1 versus 2 or 3 versus
-Fetoprotein; bHCG,  subunit of human chorionic gonadotropin; NGCCApatients alive and well after an average follow-up of 5.1
The Journal of Thoraciyears (range, 0.1-18.1 years). Twelve patients are alive
with disease after a mean follow-up of 2.6 years (range,
0.3-8.5 years). Of the 62 patients who have died during
follow-up, 53 died of disease, 2 died of nondisease, and
7 died of unknown causes. One patient has been lost to
follow-up. Considering the 65 patients who experienced
recurrent disease, 31 were found to have the first evi-
dence of recurrence within the thorax, and 23 had recur-
rence in an extrathoracic location.
Of 17 variables analyzed, older age, the requirement for
pulmonary metastasectomy, and removing 4 or more in-
trathoracic metastases predicted significantly diminished
survival (Table 2). There was significantly better survival
comparing patients who only underwent mediastinal metas-
tasectomy compared with that among patients after lung
metastasectomy or with removal of malignant disease from
both the mediastinum and the lung (P  .04, Figure 1).
Twenty-six (53.1%) of 49 patients are alive and well who
underwent removal of mediastinal disease only compared
with 31 (36.4%) of 85 who are alive and well after removal
of lung disease with or without removal of mediastinal
disease. Considering the patients who underwent removal of
pulmonary metastases, 43 underwent resection of 1 pulmo-
d Confidence
interval P value
1.02-1.09 .01*
0.66-1.02 .08
0.71-1.31 .84
0.55-1.02 .07
0.50-2.05 .96
0.57-2.14 .77
0.46-1.28 .31
0.52-2.81 .66
0.94-1.05 .76
0.38-1.42 .35
0.80-2.39 .24
0.42-1.15 .15
0.64-1.38 .75
1.16-3.62 .01*
0.73-2.42 .35
0.88-4.68 .12
1.12-2.18 .01*
0.46-1.22 .25
AFP, 0 to 100 ng/mL versus greater than 100 ng/mL; location of cancer,
astases, 1 versus 2 or more; no. of mediastinal metastases, 1 versus 2 or
more; pathology, NSGCT vs NGCCA vs both NSGCT and NGCCA. AFP,
–germ cell cancer. *P  .01.Hazar
ratio
1.05
0.82
0.97
0.75
1.02
1.10
0.77
1.21
0.99
0.73
1.39
0.69
0.94
2.05
1.33
2.02
1.56
0.75
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metastases demonstrated a median survival of 2.5 years
(Figure 2). Although this difference was not statistically
significant (P  .48), patients undergoing resection of 2 or
more pulmonary metastases had a shorter duration of
follow-up. Of the patients who underwent removal of me-
diastinal metastases, there was a trend toward better survival
in the 64 patients who underwent removal of 1 area of
malignant disease compared with the 11 who underwent
removal of 2 or more malignant areas (P  .06, Figure 3).
Combining both anatomic areas, 56 patients who underwent
one metastasectomy in the lung or mediastinum had signif-
icantly better survival than did the 28 patients who had 4 or
more areas of metastatic disease removed (P .01). The 50
patients who had 2 or 3 areas of malignant disease removed
demonstrated intermediate survival (P  .08 vs 1 area and
P  .09 vs 4 areas, Figure 4). Overall, 30 (53.6%) of 56
patients who underwent a single metastasectomy either
from the lung or mediastinum are alive and well at last
follow-up, whereas only 8 (28.6%) of 28 patients are alive
and well who underwent removal of 4 or more total areas of
malignant disease. Eighteen (36.0%) patients are alive and
Figure 1. Survival on the basis of the anatomic site of resection.
Patients who underwent removal of disease from the mediasti-
num only are represented by the solid line (median survival, 11.4
years; confidence interval [CI], 6.8-16.1), patients who underwent
removal of disease from both the mediastinum and lung are
represented by the dashed line (median survival, 3.2 years; CI,
1.6-4.7), and patients who underwent removal of disease from the
lung only are represented by interrupted dots (median survival,
2.8 years; CI, 0.4-5.3). Patient numbers at risk are given per
2.5-year intervals.well who had 2 or 3 total areas of metastatic disease re-
412 The Journal of Thoracic and Cardiovascular Surgery ● Augumoved. With respect to pathology, the 84 patients who
demonstrated persistent NSGCTs had a median survival of
8.1 years and appeared better than the 38 patients with
NGCCA or the 12 patients who had both malignant patho-
logic categories. However, this was not statistically signif-
icant (P  .24, Figure 5). Finally, on the basis of Cox
regression analysis, there were trends toward inferior sur-
vival in patients who required removal of malignant ex-
trathoracic disease (P  .15) and patients who presented to
surgical intervention with increased bHCG levels (P  .24,
Table 2).
Discussion
Patients with nonseminomatous germ cell cancer who have
malignant residual disease, including persistent NSGCTs after
first- or second-line chemotherapy, late NSGCT relapse, and
NSGCT degeneration into NGCCA, represent approximately
10% to 13% of all patients with testicular NSGCTs.14 The
concept of surgical salvage for malignant residual disease has
been well established after RPLND over the past decade be-
cause the retroperitoneum represents the first echelon of lym-
phatic drainage and therefore the most common anatomic site
of metastases. Foster and coworkers15 recently reported on 58
Figure 2. Survival on the basis of the number of lung metastases
removed. Patients who underwent removal of 1 lung metastasis
are represented by the solid line (median survival, 3.5 years; CI
was not able to be determined because of large number of
survivors and length of survival), and patients who underwent
removal of 2 or more lung metastases are represented by the
dashed line (median survival, 2.5 years; CI, 1.0-3.9). Patient num-
bers at risk are given per 2.5-year intervals.patients with viable NSGCT in RPLND specimens and found
st 2005
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disease-free survival rates after salvage RPLND.16,17 Despite
the mediastinum representing the second echelon of lymphatic
drainage, 53% of our patients undergoing removal of malig-
nant disease only in the mediastinum were alive and well at the
time of last follow-up. Although there likely exists selection
bias in patients undergoing salvage mediastinal dissection
compared with patients undergoing salvage RPLND, this find-
ing alone establishes the salvage potential of thoracic surgery
for select patients with NSGCT.
In contrast to mediastinal metastases, hematogenous me-
tastases to the lung were found to have a statistically inferior
prognosis, with 36% of our series alive and well after
removal of malignant pulmonary disease. Other series have
reported the presence of viable NSGCT cancer compared
with benign residual disease in resected pulmonary metas-
tases to result in poor but possible long-term survival. Liu
and colleagues,4 reporting on a 28-year experience of pul-
monary metastasectomy for testicular NSGCT from Memo-
rial Sloan Kettering Cancer Center, found 70 (44%) of 157
patients had pathologic evidence of viable cancer. This
subset demonstrated 43% long-term survival, which was an
independent predictor of poor outcome. Anyanwu and as-
Figure 3. Survival on the basis of the number of mediastinal
metastases removed. Patients who underwent removal of 1 me-
diastinal metastasis are represented by he solid line (median
survival, 11.4 years; CI, 5.4-17.5), and patients who underwent
removal of 2 or more mediastinal metastases are represented by
the dashed line (median survival, 2.2 years; CI, 0.9-3.5). Patient
numbers at risk are given per 2.5-year intervals.sociates18 reported on 104 patients undergoing 117 thoracic
The Journal of Thoracisurgical procedures to remove pulmonary metastases from
NSGCTs of testicular origin, which included 38 (36%)
patients with viable tumor cells. The overall 5-year survival
in this series was 59%, with inferior survivals for the subset
of patients with viable cancer. A study from the Royal
Brompton Hospital involving 141 patients undergoing tho-
racic metastasectomy, including removal of both pulmonary
and mediastinal residual disease, for NSGCTs of testicular
origin found 46 (32%) patients to demonstrate malignant
pathology.19 This subset had a 51% five-year survival that
was significantly inferior to that of patients pathologically
demonstrating either teratoma or necrosis. Although not
specifically analyzing patients with malignant pathology,
these authors also found significantly inferior survivals for
patients undergoing pulmonary metastasectomy compared
with those patients who underwent removal of residual
mediastinal disease only.
We identified other variables that were predictive of
outcome. In our series, although a fewer number of
Figure 4. Survival on the basis of the number of lung and medi-
astinal metastases removed. Patients who underwent removal of
1 lung or mediastinal metastasis are represented by the solid line
(median survival, 11.5 years; CI was not able to be determined
because of the large number of survivors and length of survival),
patients who underwent removal of 2 or 3 lung or mediastinal
metastases are represented by dashed lines (median survival, 5.7
years; CI, 1.9-9.4), and patients who underwent removal of 4 or
more lung or mediastinal metastases are represented by inter-
rupted dots (median survival, 2.2 years; CI, 1.1-3.3). Patient num-
bers at risk are given per 2.5-year intervals.malignant metastases removed specifically from either
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survival, this difference did not reach statistical signifi-
cance, probably because of low patient numbers. When
the total number of metastases removed from both ana-
tomic sites was analyzed, however, significantly better
survival was found in patients who had removal of only
1 area compared with patients undergoing resection of 4
or more areas. This finding, in addition to the trend
toward decreased survival in patients who additionally
had extrathoracic malignant disease removed, validates
our selection strategy of offering salvage thoracic surgery
to patients requiring removal of more than one area of
malignant disease only when associated with low surgical
risks. We reserve higher-risk operations, such as large
pulmonary resections or complex mediastinal dissections
involving removal of great vessels, to patients with an
isolated area of malignant disease. Although it did not
reach statistical significance in our series, there also
appeared to be better survival in those patients patholog-
ically demonstrating persistent NSGCTs compared with
patients with NGCCA. We attribute this finding to an
institutional observation that persistent NSGCTs repre-
sent a neoplasm with a less aggressive biologic behavior,
Figure 5. Survival on the basis of lung and mediastinal pathology.
Patients pathologically demonstrating persistent NSGCTs are
represented by the solid line (median survival, 8.1 years; CI,
0.1-17.4), patients pathologically demonstrating NGCCA are rep-
resented by the dashed line (median survival, 4.5 years; CI,
0.9-8.1), and patients demonstrating both persistent NSGCTs and
NGCCA are represented by interrupted dots (median survival, 2.4
years; CI, 2.1-2.7). Patient numbers at risk are given per 2.5-year
intervals.including a relative responsiveness to adjuvant chemo-
414 The Journal of Thoracic and Cardiovascular Surgery ● Augutherapy compared with degenerative NGCCA. In this
regard, because patients with degenerative NGCCA fre-
quently do not demonstrate increased STM levels, it is
not surprising that increased preoperative -fetoprotein
or bHCG levels did not predict a poor outcome in this
subset analysis. The presence of both persistent NSGCT
and degenerative NGCCA elements in pathologic speci-
mens appeared to represent the most aggressive form of
malignant disease, with no long-term survivors in our
series to date.
There are several limitations of this study. First, we
could not determine which patients under the category of
persistent NSGCT were nonresponders to initial cispla-
tin-based chemotherapy or relapsed late. The distinction
between the 2 subgroups can be occasionally difficult,
particularly because many of these patients received ini-
tial evaluation and chemotherapy at outside institutions
before referral. Regardless, because nearly half of our
patients underwent salvage thoracic surgery within 2
years of diagnosis and initial chemotherapy, we believe
there is likely a well-balanced distribution of both sub-
groups represented in the persistent NSGCT category.
Moreover, because the time from diagnosis to salvage
thoracic surgery was not predictive of outcome, we spec-
ulate that these 2 clinical scenarios, both of which result
in pathologic evidence of persistent NSGCT, might not
have significantly dissimilar outcomes. We did not have
sufficient data to determine whether disease recurring
within the thorax represented a failure of local surgical
control or occurred in other areas of the lung, mediasti-
num, or both, as a result of disease progression. It is our
general impression that the surgical approach we use to
remove residual malignant disease in the lung and medi-
astinum has resulted in few local recurrences; however,
further study is needed. Small numbers of patients with
long-term follow-up after resection of multiple areas of
malignant disease, although reflecting an institutional
trend over the study period toward a more aggressive
thoracic surgical approach in these patients, precludes
statistical analysis to determine ultimate efficacy. Finally,
we are unable to determine what fraction of these patients
pathologically demonstrated malignant disease as an in-
cidental finding, which was not anticipated before surgi-
cal intervention. These patients would arguably have the
best prognoses and potentially therefore favorably influ-
ence survival outcome.
Salvage thoracic surgery to remove malignant refractory
disease represents a situation in which a significantly poorer
long-term survival is anticipated. However, an aggressive
surgical approach is selectively justified in these otherwise
young and healthy patients, with prolonged survival being
possible. We have defined risk factors associated with long-
term survival.
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